潜在内分泌干扰风险防晒剂的监管及其使用情况分析

Supervision and use analysis of sunscreen with potential endocrine disruption risk

欧盟对具有潜在内分泌干扰风险的化妆品原料进行筛查并建立了化妆品原料优先评估清单,该清单包含了4个欧盟化妆品指令准用防晒剂。文章以优先评估清单中的防晒剂为研究对象,对其在欧盟、美国等国家(地区)的监管情况和在我国的使用情况进行概述和分析,并汇总欧盟消费者安全科学委员会的再评估结果。经研究调查发现,优先评估清单中防晒剂在我国的法规限值与美国、日本和韩国规定基本一致,但部分防晒剂限值较欧盟新修订限值高,可能存在安全风险。建议监管部门综合评估上述防晒剂的安全风险、实际使用情况和行业发展等因素,通过进一步评估和细化法规限值,以期更好地保障民众用妆安全。

The European Union has screened cosmetic ingredients with potential endocrine disrupting risks and established a priority assessment list for cosmetic ingredients,which includes four EU cosmetics directive approved sunscreens.This article focuses on the priority evaluation list of sunscreens,provides an overview and analysis of their regulatory status in countries(regions)such as the European Union and the United States,as well as their use in China.It also summarizes the reevaluation results of the European Union Consumer Safety Scientific Committee.After research and investigation,it is found that the regulatory limits for sunscreen in China on the priority evaluation list are basically consistent with those in the United States,Japan,and South Korea.However,some sunscreen limits are higher than the newly revised limits in the European Union,which may pose safety risks.It is recommended that regulatory authorities comprehensively evaluate the safety risks,actual usage,and industry development of the above-mentioned sunscreen agents,and further evaluate and refine regulatory limits to better ensure the safety of people’s makeup use.